Tradename | Proper name | Company | Number | Date | Products |
---|---|---|---|---|---|
Increlex | mecasermin | Ipsen Biopharmaceuticals, Inc. | N-21839 RX | 2005-08-30 | 1 products |
Brand Name | Status | Last Update |
---|---|---|
hucord hscm-100 ampoule | unapproved drug other | 2019-12-23 |
Expiration | Code | ||
---|---|---|---|
mecasermin, Increlex, Ipsen Biopharmaceuticals, Inc. | |||
2112-08-30 | Orphan excl. |
Code | Description |
---|---|
J2170 | Injection, mecasermin, 1 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Acromegaly | D000172 | — | — | — | 4 | 8 | 6 | 12 | 30 |
Laron syndrome | D046150 | Orphanet_633 | E34.321 | 1 | 5 | 3 | 4 | 5 | 17 |
Heart failure | D006333 | HP_0001635 | I50 | 1 | 2 | — | 1 | 2 | 5 |
Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | — | — | 2 | 2 | 4 |
Cardiovascular diseases | D002318 | HP_0001626 | — | 1 | 1 | — | 1 | — | 3 |
Brain injuries | D001930 | — | S06.9 | — | — | — | 1 | 1 | 2 |
Left ventricular hypertrophy | D017379 | EFO_0003896 | — | — | — | — | 1 | 1 | 2 |
Inflammation | D007249 | MP_0001845 | — | — | — | — | 1 | 1 | 2 |
Malnutrition | D044342 | EFO_0008572 | E40-E46 | — | — | 1 | 1 | — | 2 |
Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Breast neoplasms | D001943 | EFO_0003869 | C50 | 4 | 5 | 1 | — | 4 | 11 |
Obesity | D009765 | EFO_0001073 | E66.9 | — | 1 | 1 | — | 7 | 8 |
Non-small-cell lung carcinoma | D002289 | — | — | 3 | 4 | 1 | — | — | 6 |
Anorexia nervosa | D000856 | EFO_0004215 | F50.0 | 2 | 3 | 3 | — | 1 | 6 |
Graves ophthalmopathy | D049970 | EFO_1001466 | — | — | 1 | 1 | — | 3 | 5 |
Growth disorders | D006130 | — | — | — | 2 | 3 | — | 1 | 5 |
Fibromyalgia | D005356 | EFO_0005687 | M79.1 | — | 2 | 1 | — | 2 | 5 |
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | 1 | — | 2 | 3 |
Adrenocortical carcinoma | D018268 | — | — | 1 | 2 | 1 | — | — | 3 |
Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | 2 | 2 | — | 1 | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 10 | 4 | — | — | 1 | 13 |
Sarcoma | D012509 | — | — | 1 | 5 | — | — | 1 | 6 |
Colorectal neoplasms | D015179 | — | — | 2 | 3 | — | — | 1 | 5 |
Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 1 | 2 | — | — | 2 | 4 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 2 | 4 | — | — | — | 4 |
Osteoporosis | D010024 | HP_0000939 | M81.0 | 1 | 1 | — | — | 3 | 4 |
Hepatocellular carcinoma | D006528 | — | C22.0 | 1 | 1 | — | — | 2 | 4 |
Rectal neoplasms | D012004 | — | — | — | 3 | — | — | — | 3 |
Healthy volunteers/patients | — | — | — | — | 1 | — | — | 2 | 3 |
Prostatic neoplasms | D011471 | — | C61 | — | 2 | — | — | 1 | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Glioma | D005910 | EFO_0000520 | — | 3 | — | — | — | — | 3 |
Cystic fibrosis | D003550 | EFO_0000390 | E84 | 2 | — | — | — | 1 | 3 |
Aging | D000375 | GO_0007568 | R41.81 | 1 | — | — | — | 2 | 3 |
Tendinopathy | D052256 | EFO_1001434 | M77.9 | 1 | — | — | — | 1 | 2 |
Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | — | — | — | — | 1 |
Gastrointestinal neoplasms | D005770 | — | C26.9 | 1 | — | — | — | — | 1 |
Urogenital neoplasms | D014565 | EFO_0003863 | D07 | 1 | — | — | — | — | 1 |
Female genital neoplasms | D005833 | — | — | 1 | — | — | — | — | 1 |
Thoracic neoplasms | D013899 | — | — | 1 | — | — | — | — | 1 |
Macular edema | D008269 | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Cognitive dysfunction | D060825 | HP_0001268 | G31.84 | — | — | — | — | 3 | 3 |
Alzheimer disease | D000544 | EFO_0000249 | F03 | — | — | — | — | 2 | 2 |
Dementia | D003704 | EFO_0003862 | F03 | — | — | — | — | 2 | 2 |
Graves disease | D006111 | EFO_0004237 | E05.0 | — | — | — | — | 2 | 2 |
Metabolic bone diseases | D001851 | HP_0000938 | — | — | — | — | — | 2 | 2 |
Pituitary dwarfism | D004393 | EFO_1001109 | E23.0 | — | — | — | — | 2 | 2 |
Igg deficiency | D017099 | HP_0004315 | D80.3 | — | — | — | — | 2 | 2 |
Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | — | — | 2 | 2 |
Macular degeneration | D008268 | EFO_0001365 | H35.30 | — | — | — | — | 1 | 1 |
Parkinson disease | D010300 | EFO_0002508 | G20 | — | — | — | — | 1 | 1 |
Drug common name | Mecasermin |
INN | mecasermin |
Description | Mecasermin (INN) (brand name Increlex), also known as recombinant human insulin-like growth factor-1 (rhIGF-1), is a recombinant form of human insulin-like growth factor 1 (IGF-I) which is used in the long-term treatment of growth failure and short stature in children with severe primary IGF-I deficiency, for instance due to growth hormone deficiency or Laron syndrome (growth hormone insensitivity).
|
Classification | Protein |
Drug class | growth factors: insulin-like growth factors |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL1201716 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB01277 |
UNII ID | 7GR9I2683O (ChemIDplus, GSRS) |